Acrivon Therapeutics (ACRV) CDO awarded option on 94,946 shares

Rhea-AI Filing Summary

Gamelin Erick reported acquisition or exercise transactions in this Form 4 filing.

Acrivon Therapeutics granted Chief Development Officer Erick Gamelin a stock option covering 94,946 shares of common stock. The award is reported as a direct beneficial holding at a stated price of $0.0000 per option unit.

According to the vesting terms, 25% of the shares subject to the option vest on March 1, 2027. The remaining shares vest in 36 substantially equal monthly installments after that date, conditioned on Gamelin’s continuous service through each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gamelin Erick

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	94,946	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 94,946 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gamelin Erick

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.51	03/01/2026		A		94,946		(1)	02/29/2036	Common Stock	94,946	$0	94,946	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report for Erick Gamelin?

Acrivon Therapeutics granted Chief Development Officer Erick Gamelin a stock option for 94,946 shares of common stock. This option award increases his direct derivative holdings, subject to a multi‑year vesting schedule tied to continued service with the company.

How many Acrivon Therapeutics (ACRV) stock options did Erick Gamelin receive?

Erick Gamelin received a stock option covering 94,946 shares of Acrivon Therapeutics common stock. This derivative award was reported as directly owned and reflects an equity incentive intended to align his interests with long‑term shareholder value creation at the company.

When do Erick Gamelin’s new Acrivon (ACRV) options start vesting?

The stock option begins vesting on March 1, 2027, when 25% of the shares subject to the option vest. The remaining shares then vest in 36 substantially equal monthly installments, contingent on his continuous service through each vesting date.

What are the vesting terms of Erick Gamelin’s Acrivon Therapeutics (ACRV) option grant?

The option vests 25% of the covered shares on March 1, 2027, with the balance vesting in 36 substantially equal monthly installments. Each installment requires Erick Gamelin to remain in continuous service with Acrivon through the applicable vesting date.

Is Erick Gamelin’s Acrivon (ACRV) option grant a direct or indirect holding?

Erick Gamelin’s newly granted stock option is reported as a direct holding. The ownership code is listed as “D” for direct, and there is no footnote indicating that the award is held through a separate trust, partnership, or other affiliated entity.